AstaReal expands European presence with Kyolic and Lithos deals

Astaxanthin player AstaReal has acquired the Swedish and Norwegian market portfolios of garlic supplement brand Kyolic
Kyolic is a garlic supplement focused on heart and cardiovascular health (AstaReal AB/ Kyolic)

Astaxanthin player AstaReal has expanded its portfolio in the Swedish and Norwegian consumer markets with the addition of garlic supplement brand Kyolic.

Kyolic, a garlic supplement focused on heart and cardiovascular health, is supported by a scientific research profile that includes over 900 scientific publications over 50 years.

“What distinguishes the Kyolic brand is that it reflects AstaReal’s values of high quality, strong scientific foundation and a clear demand in the consumer market,” Peter Carlsson, business area manager at AstaReal, shared in a press release. “These are always our three most important criteria when considering new brands to collaborate with.”

After taking over the distribution rights of its own product, Astaxin, last year, and now adding Kyolic, AstaReal said more consumer products are already on the way.

“We will be launching yet another new brand in the near future,” Carlsson added. “It’s about creating ownership, understanding, and credibility—being close to the end consumers provides insights that strengthen the entire business. By owning the entire value chain, we can ensure even greater delivery reliability and quality.”

AstaReal stated that it has assembled an experienced team with a background in consumer health and sales to deliver its consumer product strategy.

“We have extensive experience working with different retailers [including pharmacies, health specialty stores and e-commerce],” Carlsson said. “We understand their business, and now we can offer a range that makes us an even more relevant partner.”

Lithos Ingredients distribution agreement

The company also announced a new distribution agreement with Lithos Ingredients, a subsidiary of the Lithos Food Group, to increase the availability of its AstaReal Astaxanthin in Belgium, Luxembourg and the Netherlands.

The agreement covers the AstaReal Astaxanthin ingredients in various forms, including bulk finished formulations, capsules and soft gels.

“This represents a significant milestone in expanding our distribution footprint in the Benelux market,” said Peter Ahlm, head of marketing & sales at AstaReal. “By combining our comprehensive range of value-added solutions with Lithos Ingredients’ strong market expertise, we’re better positioned to support customer innovation and growth.”

Astaxanthin

Astaxanthin is a reddish carotenoid with powerful antioxidant activity that is sourced from the microalga Haematococcus pluvialis. The ingredient can also be produced synthetically, much of which is used in aquaculture to give farmed salmon a richer pink color.

It has been studied for its antioxidant, anti-inflammatory, eye health benefits, cardioprotective properties, immune system modulatory activity and neuroprotective activities, and demand for astaxanthin supplements has grown over the years as more science emerges to support its benefits.

The carotenoid’s potential benefits for athletic performance have been studied in various trials, and astaxanthin has long had a dedicated following among the long-distance runner and triathlete communities.